Click here to view Full Prescribing Information
Indications
HICON® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.1
The thyroid gland needs iodine to produce its essential hormones that help regulate the body’s metabolism. The hormones the thyroid produces are called T3 (triiodothyronine), T4 (thyroxine), and calcitonin. The thyroid is remarkably efficient in capturing and storing iodine from one’s diet. Radioactive iodine, such as iodine-131, is captured by the thyroid in the same way. However, when iodine-131 accumulates in thyroid cells, it releases radiation that will destroy these cells. This unique ability has made iodine-131 a preferred treatment option for differentiated thyroid cancer (DTC) the most common form of thyroid cancer, and hyperthyroidism.
Kit for the Preparation of Sodium Iodide I 131 Capsules and Solution USP Therapeutic—Oral
HICON® is typically used in the following scenarios as part of DTC treatment:
-
Ablation—Destroys normal thyroid tissue following surgery
-
Facilitates long-term monitoring of any progression or spread of cancer1
-
Enhances the effectiveness of future radioiodine treatments, if needed, by allowing delivery of higher doses1
-
Adjunct therapy—Detects and destroys suspected residual disease and distant metastases
-
Minimizes risk of DTC relapse or recurrence
-
Treatment of recurrent thyroid cancer
Product Overview
Product Name
HICON® Kit for the Preparation of Sodium Iodide I 131 Capsules and Solution USP Therapeutic – Oral
Indications
HICON® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.1
Contraindications
Patients with vomiting and diarrhea [see Warnings and Precautions (5.7)].
Pregnancy [see Warnings and Precautions (5.4), see Use in Specific Populations (8.1)].
Lactation [see Warnings and Precautions (5.5)].
Patients receiving concurrent anti-thyroid therapy [see Warnings and Precautions (5.1) and Drug Interactions (7)].
Description
The concentrated solution (1 Ci per mL) is intended for use in the preparation of capsules and solution of varying strengths for oral administration for therapy.
Product Insert
Click here for view product insert
Safety Data Sheet
Click here to view SDS
Expiry Solution/Capsules
Click here to view solution and capsule expiration data
Not all Iodine-131 Is Created Equal
The leading manufacturer and supplier of radioactive iodine (I-131) in the US and Canada, Jubilant Radiopharma is committed to ensuring health care professionals have access to this important medication so they can provide high-quality care to their patients with thyroid cancer or hyperthyroidism. HICON® is a pharmaceutical-grade radioiodine that is FDA-approved and adheres to current Good Manufacturing Practices (cGMP) for quality, purity, and strength.
Reference:
1. Van Nostrand D. I131 ablation and treatment in well differentiated thyroid cancer. In: Van Nostrand D, Bloom G, Wartofsky L, Kulkarni KP, eds. Thyroid Cancer: A Guide for Patients. Pasadena, MD: Keystone Press; 2004;201-203.
DISCLAIMER:
This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.